199 related articles for article (PubMed ID: 27530328)
1. Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.
Shi Y; Daniels-Wells TR; Frost P; Lee J; Finn RS; Bardeleben C; Penichet ML; Jung ME; Gera J; Lichtenstein A
Cancer Res; 2016 Oct; 76(19):5822-5831. PubMed ID: 27530328
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction.
Lee J; Shi Y; Vega M; Yang Y; Gera J; Jung ME; Lichtenstein A
Bioorg Med Chem Lett; 2017 Oct; 27(20):4714-4724. PubMed ID: 28916338
[TBL] [Abstract][Full Text] [Related]
3. A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity.
Vega MI; Shi Y; Frost P; Huerta-Yepez S; Antonio-Andres G; Hernandez-Pando R; Lee J; Jung ME; Gera JF; Lichtenstein A
Mol Cancer Ther; 2019 Oct; 18(10):1822-1831. PubMed ID: 31395691
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor β integrates Smad 3 to mechanistic target of rapamycin complexes to arrest deptor abundance for glomerular mesangial cell hypertrophy.
Das F; Ghosh-Choudhury N; Bera A; Dey N; Abboud HE; Kasinath BS; Choudhury GG
J Biol Chem; 2013 Mar; 288(11):7756-7768. PubMed ID: 23362262
[TBL] [Abstract][Full Text] [Related]
5. TGFβ-induced deptor suppression recruits mTORC1 and not mTORC2 to enhance collagen I (α2) gene expression.
Das F; Bera A; Ghosh-Choudhury N; Abboud HE; Kasinath BS; Choudhury GG
PLoS One; 2014; 9(10):e109608. PubMed ID: 25333702
[TBL] [Abstract][Full Text] [Related]
6. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.
Peterson TR; Laplante M; Thoreen CC; Sancak Y; Kang SA; Kuehl WM; Gray NS; Sabatini DM
Cell; 2009 May; 137(5):873-86. PubMed ID: 19446321
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
Zhang H; Chen J; Zeng Z; Que W; Zhou L
Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
[TBL] [Abstract][Full Text] [Related]
9. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells.
Yang Y; Bardeleben C; Frost P; Hoang B; Shi Y; Finn R; Gera J; Lichtenstein A
Genes Cancer; 2014 Nov; 5(11-12):407-19. PubMed ID: 25568666
[TBL] [Abstract][Full Text] [Related]
10. Akt2 causes TGFβ-induced deptor downregulation facilitating mTOR to drive podocyte hypertrophy and matrix protein expression.
Das F; Ghosh-Choudhury N; Lee DY; Gorin Y; Kasinath BS; Choudhury GG
PLoS One; 2018; 13(11):e0207285. PubMed ID: 30444896
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
12. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
Gera J; Lichtenstein A
Leuk Lymphoma; 2011 Oct; 52(10):1857-66. PubMed ID: 21599581
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma.
Yen CH; Lu YC; Li CH; Lee CM; Chen CY; Cheng MY; Huang SF; Chen KF; Cheng AL; Liao LY; Lee YH; Chen YM
Mol Med; 2012 Mar; 18(1):286-96. PubMed ID: 22160218
[TBL] [Abstract][Full Text] [Related]
14. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
Cirstea D; Santo L; Hideshima T; Eda H; Mishima Y; Nemani N; Mahindra A; Yee A; Gorgun G; Hu Y; Ohguchi H; Suzuki R; Cottini F; Guichard SM; Anderson KC; Raje N
Mol Cancer Ther; 2014 Nov; 13(11):2489-500. PubMed ID: 25172964
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
16. Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation.
Vega M; Chen Y; Shi Y; Gera J; Lichtenstein A
J Biol Chem; 2022 Apr; 298(4):101750. PubMed ID: 35216969
[TBL] [Abstract][Full Text] [Related]
17. Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells.
Catena V; Bruno T; De Nicola F; Goeman F; Pallocca M; Iezzi S; Sorino C; Cigliana G; Floridi A; Blandino G; Fanciulli M
Oncotarget; 2016 Oct; 7(43):70546-70558. PubMed ID: 27655709
[TBL] [Abstract][Full Text] [Related]
18. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
Hoang B; Frost P; Shi Y; Belanger E; Benavides A; Pezeshkpour G; Cappia S; Guglielmelli T; Gera J; Lichtenstein A
Blood; 2010 Nov; 116(22):4560-8. PubMed ID: 20686120
[TBL] [Abstract][Full Text] [Related]
19. Rapid mitogenic regulation of the mTORC1 inhibitor, DEPTOR, by phosphatidic acid.
Yoon MS; Rosenberger CL; Wu C; Truong N; Sweedler JV; Chen J
Mol Cell; 2015 May; 58(3):549-56. PubMed ID: 25936805
[TBL] [Abstract][Full Text] [Related]
20. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.
Quwaider D; Corchete LA; Misiewicz-Krzeminska I; Sarasquete ME; Pérez JJ; Krzeminski P; Puig N; Mateos MV; García-Sanz R; Herrero AB; Gutiérrez NC
J Hematol Oncol; 2017 Apr; 10(1):92. PubMed ID: 28420429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
